title: Interferon-alfa- and erythropoetin-associated cerebral vasoconstriction.
authors.forename: N
authors.initials: N
authors.lastname: Gaillard
authors.forename: A
authors.initials: A
authors.lastname: Mania
authors.forename: H
authors.initials: H
authors.lastname: Brunel
authors.forename: F
authors.initials: F
authors.lastname: Blanc
authors.forename: C
authors.initials: C
authors.lastname: Arquizan
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D000068256:Darbepoetin alfa; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D051270:Headache Disorders, Primary / Q000139:chemically induced*; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects*; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D011994:Recombinant Proteins; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D006397:Hematinics; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa